Unleashing the power of proteomics to develop blood-based cancer markers

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 119-126

  Taguchi, Ayumu ^a   Hanash, Samir M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN ANTIBODY; PROTEOME; TUMOR MARKER;

BLOOD ANALYSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; LUNG CANCER; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MICROARRAY; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; TUMOR IMMUNITY; VALIDATION STUDY;

ANTIBODY FORMATION; HUMANS; MASS SPECTROMETRY; NEOPLASM PROTEINS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

HARNESS;

EID: 84872017894     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.184572     Document Type: Review

References (59)

1. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452:571-9. (Pubitemid 351483371)
2. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat Rev Cancer 2010;10:652-60.
3. Nilsson T, Mann M, Aebersold R, Yates JR 3rd, Bairoch A, Bergeron JJ. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat Methods 2010;7:681-5.
4. Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010;152:505-12.
5. Chubak J, Boudreau DM, Fishman PA, Elmore JG. Cost of breast-related care in the year following false positive screening mammograms. Med Care 2010;48:815-20.
6. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
7. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol 2012;29:543-9.
8. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999;354:99-105. (Pubitemid 29313143)
9. Henschke C, Naidich D, Yankelevitz D, McGuinness G, McCauley D, Smith J, et al. Early lung cancer action project: initial findings on repeat screening. Cancer 2001;92:153-9. (Pubitemid 32623052)
10. Kaneko M, Eguchi K, Ohmatsu H, Kakunuma R, Naruke T, Suemasu K, Moriyama N. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
11. Sobue T, Moriyama N, Kaneko M, Kusumoso M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002;20:911-20. (Pubitemid 34141832)
12. Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001;84:25-32. (Pubitemid 32102499)
13. Li F, Sone S, Abe H, Macmahon H, Doi K. Malignant versus benign nodules at CT screenings for lung cancer: comparison of thin-section CT findings. Radiology 2004;223:793-8.
14. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002;165:508-13. (Pubitemid 34165474)
15. Swensen SJ, Jett JR, Hartman JE, Midthun DE, Mandrekar S, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-65. (Pubitemid 40432263)
16. Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, Heindel W. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002;222:773-81. (Pubitemid 34215229)
17. Nawa T, Nakagawa T, Kusano S, Kawasaki Y, Sugawara Y, Nakata H. Lung cancer screening using low-dose spiral CT: Results of baseline and 1-year follow-up studies. Chest 2002;122:15-20. (Pubitemid 34754137)
18. McWilliams AM, Mayo JR, Ahn MI, MacDonald SL, Lam SC. Lung cancer screening using multislice thin-section computed tomography and autofluorescence bronchoscopy. J Thorac Oncol 2006;1:61-8. (Pubitemid 47164022)
19. Pastorino U, Bellomi M, Landoni C, De Flori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-7. (Pubitemid 37013298)
20. Roberts HC, Patsios D, Paul NS, McGregor M, Weisbrod G, Chung T, et al. Lung cancer screening with low dose computed tomography: Canadian experience. Can Assoc Radiol J 2007;58:225-35. (Pubitemid 350021946)
21. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol 2011;29:543-9.
22. Holm A, Wu W, Lund-Johansen F. Antibody array analysis of labeled proteomes: how should we control specificity? N Biotechnol 2012;29:578-85.
23. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007;6:3558-65. (Pubitemid 47522747)
24. Zhang Q, Faca V, Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res 2011;10:46-50.
25. Michalski A, Damoc E, Lange O, Denisov E, Nolting D, Muller M, et al. Ultra high resolution linear ion trap Orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol Cell Proteomics 2012;11:O111.013698.
26. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477-88. (Pubitemid 40861990)
27. Zhang H, Liu AY, Loriaux P, Wollscheid B, Zhou Y, Watts JD, Aebersold R. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007;6:64-71. (Pubitemid 46152692)
28. Zeng Z, Hincapie M, Pitteri SJ, Hanash S, Schalkwijk J, Hogan JM, et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem 2011;83:4845-54.
29. Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem 2008;54:1166-75. (Pubitemid 352009693)
30. Wang H, Wong CH, Chin A, Taguchi A, Taylor A, Hanash S, et al. Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. Nat Protoc 2011;6:253-69.
31. Ramirez AB, Lampe PD. Discovery and validation of ovarian cancer biomarkers utilizing high density antibody microarrays. Cancer Biomark 2010;8:293-307.
32. Ostroff RM, Bigbee WL, Franklin W, Gold L, Mehan M, Miller YE, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLOS One 2010;5:e15003.
33. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001;61:7908-12. (Pubitemid 33049381)
34. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. An immune response manisfested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 2001;98:9824-9. (Pubitemid 32769388)
35. Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res 2007;67:12000-6.
36. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-6.
37. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011;20:289-99.
38. Liotta LA, Petricoin E. Cancer biomarkers: closer to delivering on their promise. Cancer Cell 2011;20:279-80.
39. Omenn GS, States DJ, Adamski M, Blackwell T, Menon R, Hermjakob H, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-45. (Pubitemid 41192032)
40. States DJ, Omenn GS, Blackwell TW, Fermin D, Eng J, Speicher DW, Hanash SM. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006;24:333-8. (Pubitemid 43372157)
41. Jones P, Cote RG, Martens L, Quinn AF, Taylor CF, Derache W, et al. PRIDE: A public repository of protein and peptide identifications for the proteomics community. Nucleic Acids Res 2006;34:D659-63.
42. Deutsch EW, Eng JK, Zhang H, King NL, Nesvizhskii AI, Lin B, et al. Human plasma peptideatlas. Proteomics 2005;5:3497-500. (Pubitemid 41192054)
43. Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, et al. UniPep-a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol 2006;7:R73.
44. Craig R, Cortens JP, Beavis RC. Open source system for analyzing, validating, and storing protein identification data. J Proteome Res 2004;3:1234-42. (Pubitemid 40040378)
45. Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, et al. Human protein-pedia enables sharing of human protein data. Nat Biotechnol 2008;26:164-7. (Pubitemid 351225942)
46. Gaster RS, Hall DA, Nielsen CH, Osterfeld SJ, Yu H, Mach KE, et al. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med 2009.
47. Gaster RS, Hall DA, Wang SX. Autoassembly protein arrays for analyzing antibody cross-reactivity. Nano Lett 2010.
48. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-6. (Pubitemid 47123194)
49. Serkova NJ, Glunde K. Metabolomics of cancer. Methods Mol Biol 2009;520:273-95.
50. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Rolf-Dieter H, Knippers R. DNA fragments in the blood plasma of cancer patients: quantifications and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65. (Pubitemid 34292602)
51. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006;52:1833-42. (Pubitemid 44470688)
52. Zangar RC, Daly DS, White AM. ELISA microarray technology as a high-throughput system for cancer biomarker validation. Expert Rev Proteomics 2006;3:37-44. (Pubitemid 43979390)
53. Kim YW, Bae SM, Kim IW, Liu HB, Bang HJ, Chaturvedi PK, et al. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Oncol Rep 2012;28:585-91.
54. Gu GJ, Friedman M, Jost C, Johnsson K, Kamali-Moghaddam M, Pluckthun A, et al. Protein tag-mediated conjugation of oligonucleotides to recombinant affinity binders for proximity ligation. N Biotechnol. [Epub ahead of print 2012 Jun 2].
55. Xue Q, Wang Z, Wang L, Jiang W. Sensitive detection of proteins using assembled cascade fluorescent DNA nanotags based on rolling circle amplification. Bioconjug Chem 2012;23:734-9.
56. Ilyas A, Asghar W, Allen PB, Duhon H, Ellington AD, Iqbal SM. Electrical detection of cancer biomarker using aptamers with nanogap break-junctions. Nanotechnology 2012;23:275502.
57. Vaisocherova H, Faca VM, Taylor AD, Hanash S, Jiang S. Comparative study of SPR and ELISA methods based on analysis of CD166/ALCAM levels in cancer and control human sera. Biosens Bioelectron 2009;24:2143-8.
58. Lemoine J, Fortin T, Salvador A, Jaffuel A, Charrier JP, Choquet-Kastylevsky G. The current status of clinical proteomics and the use of MRM and MRM(3) for biomarker validation. Expert Rev Mol Diagn 2012;12:333-42.
59. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009;8:995-1005.